Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Interleukin 13 is a central mediator of asthma. Tralokinumab is a human interleukin-13 neutralising monoclonal antibody. We aimed to assess the efficacy and safety of two dosing regimens of tralokinumab in patients with severe uncontrolled asthma.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Respir Med

Title: The Lancet. Respiratory medicine

ISSN (Electronic): 2213-2619

ISSN (Print): 2213-2600

Publication date (Electronic): Sep 2015

Volume: 3

Issue: 9

Affiliations

[1 ] University of Leicester, Leicester, UK.

[2 ] Département des Maladies Respiratoires, CIC Nord APHM, Laboratoire INSERM CNRS U 1067, UMR7333, Aix-Marseille Université, Marseille, France.

[3 ] University of Calgary, Calgary, AB, Canada.

[4 ] McMaster University, Hamilton, ON, Canada.

[5 ] Johannes Gutenberg University Hospital, Mainz, Germany.

[6 ] MedImmune, Gaithersburg, MD, USA.

[7 ] MedImmune, Cambridge, UK.

[8 ] MedImmune, Cambridge, UK. Electronic address: edward.piper@astrazeneca.com.

Article

Publisher Item ID: S2213-2600(15)00197-6

DOI: 10.1016/S2213-2600(15)00197-6

PubMed ID: 26231288

SO-VID: 16578503-1d07-461e-abb2-93a6f051bbd6

History

Data availability:

Comments

Comment on this article

scite_

Cited by 116

See all cited by

- Version 1